Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Cash from Financing Activities: 2010-2025

Historic Cash from Financing Activities for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Sep 2025 value amounting to $74.0 million.

  • Arrowhead Pharmaceuticals' Cash from Financing Activities fell 99.06% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.0 million, marking a year-over-year decrease of 91.50%. This contributed to the annual value of $74.0 million for FY2025, which is 91.50% down from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Cash from Financing Activities stood at $74.0 million for FY2025, which was down 91.50% from $870.5 million recorded in FY2024.
  • Arrowhead Pharmaceuticals' 5-year Cash from Financing Activities high stood at $870.5 million for FY2024, and its period low was $11.3 million during FY2021.
  • Over the past 3 years, Arrowhead Pharmaceuticals' median Cash from Financing Activities value was $253.1 million (recorded in 2023), while the average stood at $399.2 million.
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' Cash from Financing Activities slumped by 95.62% in 2021, and later spiked by 476.61% in 2022.
  • Arrowhead Pharmaceuticals' Cash from Financing Activities (Yearly) stood at $11.3 million in 2021, then spiked by 476.61% to $65.2 million in 2022, then skyrocketed by 288.20% to $253.1 million in 2023, then spiked by 244.01% to $870.5 million in 2024, then slumped by 91.50% to $74.0 million in 2025.